Medicine and Dentistry
Hepatitis C Virus
87%
Miravirsen
75%
Virus RNA
50%
microRNA 122
37%
Chronic Hepatitis C
25%
Infection
25%
Virus Genome
25%
Hepatitis C Virus Genotype 1
25%
Therapeutic Procedure
25%
Follow up
12%
Body Weight
12%
microRNA
12%
Antisense Oligonucleotide
12%
Combination Therapy
12%
Adverse Event
12%
Subcutaneous Injection
12%
Hepatitis C
12%
Binding Site
12%
Virus Resistance
12%
Locked Nucleic Acid
12%
Heteroduplex
12%
Liver
12%
Pharmacology, Toxicology and Pharmaceutical Science
Hepatitis C Virus
87%
Miravirsen
75%
microRNA 122
37%
Infection
25%
Chronic Hepatitis C
25%
Hepatitis C Virus Genotype 1
25%
Binding Site
12%
Adverse Event
12%
DNA
12%
Subcutaneous Injection
12%
Antisense Oligonucleotide
12%
Hepatitis C
12%
Locked Nucleic Acid
12%
Virus Resistance
12%
Thiophosphate
12%
microRNA
12%
Heteroduplex
12%
Immunology and Microbiology
Hepatitis C Virus
100%
Dose
50%
Reduction (Chemistry)
50%
Virus Genome
25%
Hepatitis C Virus Genotype 1
25%
Binding Site
12%
Body Weight
12%
Mutation
12%
Virus Resistance
12%
Liver
12%
Viral Disease
12%
Nursing and Health Professions
Miravirsen
75%
microRNA 122
37%
Locked Nucleic Acid
12%
Heteroduplex
12%